Rakuten Aspyrian Revenue and Competitors

Location

#5576

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • Rakuten Aspyrian's estimated annual revenue is currently $29.6M per year.(i)
  • Rakuten Aspyrian received $134.0M in venture funding in December 2018.
  • Rakuten Aspyrian's estimated revenue per employee is $193,750
  • Rakuten Aspyrian's total funding is $618.6M.

Employee Data

  • Rakuten Aspyrian has 153 Employees.(i)
  • Rakuten Aspyrian grew their employee count by 61% last year.

Rakuten Aspyrian's People

NameTitleEmail/Phone
1
Vp, Global People OperationsReveal Email/Phone
2
VP FinanceReveal Email/Phone
3
VP Clinical Development, Rakuten Aspyrian Japan K.KReveal Email/Phone
4
Chief Technology OfficerReveal Email/Phone
5
President & COOReveal Email/Phone
6
Dir, Corporate & Business DevelopmentReveal Email/Phone
7
DIR Strategic Planning/Operations/Head Asia Business Promotion, Rakuten Aspyrian JapanReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.3M1515%N/AN/A
#5
$1.6M10-17%N/AN/A
#6
$0.7M950%N/AN/A
#7
$11.5M74-12%N/AN/A
#8
$0.4M27510%$236.7MN/A
#9
$4M51-74%$160MN/A
#10
$2.3M1515%N/AN/A
Add Company

What Is Rakuten Aspyrian?

Rakuten Aspyrian, Inc., is a privately funded clinical stage biotechnology company with offices in the USA, Japan and Germany. Since 2013, Rakuten Aspyrian has been developing new anticancer therapies based on the Photoimmunotherapy platform. Rakuten Aspyrian plans to become a fully integrated biopharma with research, development, and world-wide commercialization of therapies based on the Photoimmunotherapy platform. Our long-term objective is to commercialize a number of therapies based on Photoimmunotherapy to treat a broad range of solid tumor types as single agent and in combination with other immunomodulatory agents to generate robust and long lasting anticancer immunological responses. Rakuten Aspyrian is currently sponsoring a global Phase 3 multicenter clinical study for ASP-1929 to evaluate the efficacy and safety of ASP-1929 in patients with recurrent Head and Neck Cancer and additional Phase 2 studies to evaluate the safety and efficacy of ASP-1929 in patients with other cancer types. Given the rapid progression of the clinical studies, we are quickly expanding the team to support late stage pivotal clinical development and future commercialization of our products.

keywords:N/A

$618.6M

Total Funding

153

Number of Employees

$29.6M

Revenue (est)

61%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Rakuten Aspyrian News

2019-03-01 - Rakuten Aspyrian Announces Name Change to Rakuten ...

SAN MATEO, Calif., March 1, 2019 /PRNewswire/ -- Rakuten Aspyrian, a biotechnology company developing precision-targeted cancer ...

2018-12-21 - Rakuten Aspyrian Closes $284M Series C Financing

Rakuten Aspyrian, a San Mateo, California, CA-based biotechnology company developing precision-targeted cancer therapies based on its proprietary Photoimmunotherapy platform, raised an additional $134m in a second tranche of its Series C financing, bringing the total amount raised to $284m. Bac ...

2018-12-20 - Rakuten Aspyrian Closes $284 Million Series C Financing for ...

SAN FRANCISCO, Dec. 20, 2018 /PRNewswire/ -- Rakuten Aspyrian, a biotechnology company developing precision-targeted cancer ...

2018-12-17 - Rakuten Aspyrian Enrolling Phase 3 Trial of ASP-1929 for ...

SAN DIEGO, Dec. 17, 2018 /PRNewswire/ -- Rakuten Aspyrian, a biotechnology company developing precision-targeted cancer therapies ...

2018-08-27 - Rakuten Aspyrian Finds $150M For Cancer Treatments

San Diego-based biotechnology developer Rakuten Aspyrian announced last week that it has raised $150M for its efforts to develop treatments for head and neck cancer. According to Rakuten Aspyrian, the Series C funding round was led by Hiroshi Mikitani, the CEO of Japan's Rakuten. The company has ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$45M153-70%$248.5M
#2
$5.7M15318%$791.4M
#3
$42.7M15310%N/A
#4
$29.8M15415%$134.1M
#5
$43M15425%N/A

Rakuten Aspyrian Funding

DateAmountRoundLead InvestorsReference
2018-08-24$150.0MCRakuten IncArticle
2018-12-21$134.0MCSBI GroupArticle